Chemotherapy combination for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, as the first treatment for pancreatic cancer that has spread. The goal is to shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed diagnosis of pancreatic cancer that has spread to other organs (metastatic).
- If you've had chemotherapy before (especially after surgery), it must have finished more than 6 months ago.
- You should be able to perform daily activities with some help (ECOG score 0-2).
- Your blood counts, liver and kidney function must be within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for pancreatic cancer that hasn't spread. It aims to see if the combination can shrink tumors and improve survival with manageable side effects.
This study tests a chemotherapy drug (nab-paclitaxel) combined with other treatments for people with pancreatic cancer. The goal is to see if this combination helps control the cancer or prevents it from coming back after surgery.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.